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Given the prevalence of irritable bowel syndrome (IBS) and the suboptimal response to 
most therapeutic approaches, there has been increasing interest in and adoption of 
dietary treatment strategies, such as the low Fermentable Oligo- , Di- , & Mono- 
Saccharides	and	Polyols	(FODMAP)	diet.	FODMAPs	are	a	diverse	group	of	carbohy-
drates that exert effects in the gastrointestinal tract not only via fermentation but likely 
via alterations in the microbiota, metabolome, permeability, and intestinal immunity as 
well. Clinical evidence for efficacy of this diet is mounting, but there are significant 
questions regarding short- and long- term safety and effects on the microbiota and 
nutrition that remain unanswered. This review article interprets the recent findings 
reported in this issue of Neurogastroenterology and Motility and summarizes the mecha-
nistic	and	clinical	efficacy	data	of	the	low	FODMAP	diet	in	IBS	patients	to	date.
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1  | INTRODUCTION
Irritable bowel syndrome (IBS) is a prevalent condition that leads to 
considerable morbidity and disability.1 Despite this, healthcare expen-
ditures for the treatment of organic diseases consume a disproportion-
ate portion of the healthcare pie and leave little for so- called “quality 
of life” disorders like IBS. In addition, the heterogeneity inherent to the 
phenotype and pathogenesis of IBS has created significant challenges 
in drug therapy development for this chronic disease, and the absolute 
therapeutic gain from traditional therapies has been marginal, typi-
cally ranging from 7% to 15%.2As	a	consequence,	providers	and	IBS	
patients are increasingly being forced to find solutions for their symp-
toms that do not involve prescription medications. When one con-
siders that two- thirds of IBS patients associate their symptoms with 
eating a meal,3,4 the importance of finding effective, evidence- based 
dietary solutions becomes obvious. Furthermore, IBS patients are de-
manding more “natural,” accessible, cost- effective, and safe options 
to treat their disease. Unfortunately, traditional dietary advice for IBS 
patients, such as regulating fiber intake or fat content, is not evidence- 
based and often has proven ineffective.5–8	Thus,	 the	 low	FODMAP	
(Fermentable Oligo- , Di- , & Mono- Saccharides and Polyols) diet has 
been gaining popularity for the treatment of this condition. This review 
article interprets the recent findings of Hustoft et al.9 reported in this 




FODMAPs	 are	 a	 diverse	 group	 of	 poorly	 absorbed	 carbohydrates	
thought to contribute to gastrointestinal symptoms, likely via mul-
tiple pathways (Figure 1). Conventional thinking has focused on the 
cumulative	effects	of	consuming	excessive	amounts	of	all	FODMAPs.	
Undigested,	non-	absorbed	FODMAPs	create	an	osmotic	load	and	are	
then fermented by small intestinal and colonic bacteria. This leads 
to the production of short chain fatty acids and gases (hydrogen, 
methane, carbon dioxide), which can trigger symptoms particularly 
in patients who have underlying abnormalities in gut motility and 
visceral sensation.10,11 Collectively, these effects can exert primary 
and secondary effects on motility, visceral sensation, and the gut mi-
crobiota that may result in symptoms of cramping, bloating, disten-
tion, and flatulence in a subset of IBS patients.12–14 However, recent 
work	 suggests	 that	 the	 various	 FODMAPs	 exert	 different	 effects	
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along the GI tract parts of the GI tract. Using functional magnetic 
resonance imaging (fMRI), investigators from the UK showed differ-
ential effects of fructose and fructans in the small intestine and colon 
in healthy volunteers and IBS patients.15,16	After	fructose	and	inulin	
(a fructan) challenges, healthy controls had significantly lower symp-
tom scores after either fructose or inulin consumption than patients 
with IBS, despite similar fMRI parameters and breath hydrogen re-
sponses.16 Fructose led to increased small- bowel water content in 
both IBS patients and controls (potentially accelerating small- bowel 
transit and peristalsis as well) whereas inulin increased colonic vol-
ume and gas via fermentation by resident bacteria. This indicates 
that colonic hypersensitivity, rather than greater gas production or 
distension,	drives	FODMAP-	related	symptoms	in	some	IBS	patients.
Apart	 from	 fermentation	 effects,	 FODMAPs	 may	 also	 gen-
erate symptoms via immune activation. Given that wheat prod-
ucts	 contain	 high	 FODMAP	 content,	 predominantly	 fructans	 and	
galacto- oligosaccharides (GOS), studies focusing on non- celiac 
wheat sensitivity (NCWS) may be potentially extrapolated to IBS pa-
tients.17,18 Possible mechanisms for NCWS (and thus a response to a 
low	FODMAP	diet)	 include	 increased	 intestinal	permeability	of	 tight	
junctions or stimulation of lamina propria macrophages leading to pro- 
inflammatory cytokines.19,20 Histamine, a signaling molecule known to 
underlie	 IBS	 symptoms,	may	 also	 be	 affected	 by	 the	 low	FODMAP	
diet. McIntosh et al.21 compared urinary metabolomic profiles of 40 
IBS	patients	after	21	days	of	a	low-	or	high-	FODMAP	diet.	Following	
dietary intervention there was a significant separation in urinary me-
tabolomic profiles of patients with IBS in the two diet groups. In the 
low	 FODMAP	 diet	 group,	 urinary	 histamine	 level	 decreased	 signifi-
cantly after the intervention (P<.05)	compared	to	the	high-	FODMAP	
group. The authors postulate that degranulation of mast cells may 
occur	due	to	direct	signaling	from	short	chain	fatty	acids	 (SCFAs)	or	
from intestinal distension via fermentation, thereby modulating IBS 
symptoms.
3  | EVIDENCE OF CLINICAL BENEFIT
There is a growing body of evidence to support the efficacy of the 
low	 FODMAP	 diet	 in	 patients	 with	 IBS	 symptoms.22–26 The first 
study	 demonstrating	 a	 link	 between	 dietary	 FODMAPs	 and	 symp-
toms	comes	from	Shepherd	and	Gibson’s	2008	Australian	work	dur-
ing which IBS patients were more likely to experience gastrointestinal 
symptoms after blinded consumption of escalating doses of fructose 
or fructans than after glucose.23 This approach was novel because 
until this time, dietary strategies focused on the elimination of a sin-
gle carbohydrate type (ie, lactose, sorbitol, fructose) rather than entire 
groups of carbohydrates. Subsequent retrospective and randomized 
studies	 of	 dietary	 FODMAP	 restriction	 have	 reported	 symptomatic	
improvement in 52%–76% of IBS patients.11,24,27–29 Many studies in-
volving diet for IBS suffer from placebo effect, limited duration, lack of 
rigorous endpoints, lack of randomization/blinding, and limited dietary 
assessment to confirm adherence.
The	 results	of	 randomized	controlled	 trials	 for	 the	 low	FODMAP	
diet in IBS patients in IBS patients have not been uniformly positive, es-
pecially when compared with active interventions in a more “real world” 
setting where food was not supplied to subjects.30,31 Bohn et al.31 
F IGURE ­1 Mechanisms by which 
Fermentable Oligo- , Di- , & Mono- 
Saccharides and Polyols s may cause 
Gastrointestinal	symptoms.	Adapted	
from Spencer M, et al. Current treatment 


































exert their effects along the GI tract.
•	 A	low	FODMAP	diet	is	likely	helpful	in	treating	IBS	symp-
toms, but the evidence is not entirely supportive of this 
approach.
•	 The	low	FODMAP	diet	has	potential	limitations,	including	
effects on the intestinal microbiota and metabolome.
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compared	the	low	FODMAP	diet	to	standard	dietary	advice	and	found	
that about half of each group improved with the intervention, with no 
significant difference between the two groups after 4 weeks. Each 
group received dietitian counseling, and all IBS subtypes were included. 
Similar improvements in each group were noted for most individual 
symptoms as well (bloating, abdominal pain). Our group recently com-
pleted the first US comparative effectiveness trial comparing the low 
FODMAP	diet	vs	usual	dietary	recommendations	in	IBS	patients	with	
diarrhea (IBS- D) using a similar study design in 92 patients.30 There was 
no significant difference between the interventions for the primary 
endpoint	of	adequate	relief	(52%	with	a	low	FODMAP	diet	vs	41%	with	
usual dietary recommendations. However, a significantly greater pro-
portion	in	low	FODMAP	diet	group	than	the	usual	dietary	recommen-
dation group experienced improvement in abdominal pain and bloating, 
two of the most bothersome complaints associated with IBS. In addi-
tion, significant improvements were seen in stool consistency, stool fre-
quency, and urgency compared to usual dietary recommendations for 
IBS. Significant improvements in quality of life measures, as well as anx-
iety	were	seen	in	the	low	FODMAP	diet	compared	to	usual	dietary	rec-
ommendations for IBS.32 The primary endpoints were negative in both 
trials that utilized an active comparator and dietitian- directed dietary 
interventions,	highlighting	some	of	the	limitations	of	the	low	FODMAP	
diet in the clinical setting (see below). However, the results for the 
secondary endpoints differed, likely explained by intrinsic differences 
in genetics, microbiome, diet, and cultural issues between the study 




shortcomings. This approach, while clinically effective, is highly restric-
tive and may be confusing to administer, leading to potential problems 
with	adherence.	Another	issue	is	that	the	full	elimination	phase	is	not in-
tended to be continued indefinitely; if a patient improves during the full 
elimination phase, providing tailored dietary counseling to re- introduce 
FODMAP	containing	food	groups	to	arrive	at	each	individual’s	version	
of	the	low	FODMAP	diet	is	recommended.	The	duration	of	the	full	low	
FODMAP	 diet	 has	 potential	 long-	term	 implications	 considering	 that	
fermentable	 carbohydrates	 such	 as	FODMAPs	provide	 substrates	 for	
“healthy” GI bacteria. Indeed, several studies comparing the effects of 
a	low	FODMAP	diet	to	a	habitual	diet	demonstrated	a	reduction	in	the	
proportion and concentration of Bifidobacteria.9,24	 Another	 study	 did	
not demonstrate a decrease in Bifidobacteria, but did show a decrease 
in total bacteria abundance,33 the consequences of which have not been 
well characterized. In addition to changing the microbiota, fermenta-
tion	creates	by-	products	such	as	SCFAs,	 including	butyrate,	providing	
nutrients and other benefits for the colonic mucosa and playing a criti-
cal role in the luminal microenvironment (Figure 1).34 Thus, while the 
low	 FODMAP	 diet	 may	 improve	 GI	 symptoms,	 long-	term	 avoidance	
of	 FODMAPs	 may	 have	 potentially	 harmful	 effects	 on	 colon	 health.	
Studies	investigating	the	effects	of	the	low	FODMAP	diet	on	the	colon	




In this issue, Hustoft et al.9 report the results of a crossover study 
designed to investigate the importance of fructo- oligosaccharides 
(FOS)	 in	 symptom	generation	 in	 IBS	 patients.	After	 3	weeks	 of	 a	 low	
FODMAP	 diet,	 20	 patients	with	 non-	constipated	 IBS	 received	 either	
10 days of FOS or placebo supplements, followed by a washout period 
of 3 weeks, followed by another 10- day cross- over period. The authors 
analyzed	inflammatory	cytokines	throughout	the	study,	and	SCFAs	and	
gut microbiota composition were analyzed as well. Most patients had 
severe IBS symptoms as measured by IBS- SSS. Interestingly, all patients 
improved	with	the	low	FODMAP	diet	 (defined	as	reduction	in	at	 least	
50 points IBS- SSS) and all patients completed the trial. When the FOS 
supplement was introduced, significantly fewer subjects reported control 
of IBS symptoms compared to placebo, with no order effect observed 
(80% vs 30%). There was a large inter- subject variability in the responses 
to	FODMAP	provocation	 (FOS	vs	placebo)	 as	 compared	 to	FODMAP	
reduction. Levels of IL-6 and Il-8 (but not TNF-α) both decreased sig-
nificantly	after	3	weeks	of	a	 low	FODMAP	diet,	with	a	median	reduc-
tion of 0.065 pg/mL and of 2.95 pg/mL, respectively. Cytokine levels did 
not change in response to FOS supplementation, however. F.prausnitzii, 
Actinobacteria, and Bifidobacterium abundance were significantly altered 
in	both	dietary	interventions	(decreased	in	low	FODMAP	diet,	increased	
again	with	FOS	supplementation).	Levels	of	 total	SCFAs	and	n-	butyric	
acid	 both	 decreased	 significantly	 following	 a	 low	 FODMAP	 diet	 as	
compared	to	baseline,	but	SCFA	levels	were	otherwise	not	significantly	
altered when comparing values from samples obtained at baseline, fol-
lowing	a	low	FODMAP	diet,	and	after	FOS	supplementation.
This manuscript from Norway addresses several unanswered ques-
tions	about	the	 low	FODMAP	diet.	Because	of	 its	cross-	over	design	
and lack of worsening symptoms with the maltodextrin placebo, it is 
clear that a placebo response is not entirely responsible for the effect 
of the diet. In addition, although IBS symptoms significantly worsened 
in response to FOS, the severity was not comparable to the symptom 
level observed at baseline. This lends weight to the belief that while 
individual	FODMAP	restriction	may	be	partially	beneficial,	collective	
FODMAP	 restriction	 (at	 least	 in	 this	 patient	 population)	may	be	 re-
quired to achieve maximum symptom response. There was however 
a larger inter- subject variability in response to the two supplements, 
supporting	the	view	that	each	patient’s	threshold/FODMAP	sensitiv-
ity is specific and may be individualized.
Based on this and other studies,21,24,33 it seems clear that the low 
FODMAP	diet	has	effects	on	the	microbiota	and	metabolome,	decreas-
ing	SCFAs	and	bacteria	thought	to	promote	GI	health.	The	fact	that	
the abundance of several bacteria (F. prausnitzii,	Actinobacteria,	 and	
Bifidobacterium) rebounded after 10 days of FOS supplementation is 
reassuring, that the effect of dietary change is temporary. However 
after	 FOS	 supplementation,	 both	 cytokine	 levels	 and	 SCFA	 levels	
were unchanged. Reasons for this are not clear—perhaps 10 days of 
FOS supplementation is not of sufficient duration, or that alternate 
FODMAPs	are	driving	those	changes.
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5  | UNANSWERED QUESTIONS
The	efficacy	of	a	low	FODMAP	diet	for	IBS	is	becoming	increasingly	
obvious but several areas remain to be clarified: (i) the mechanism(s) 
by	 which	 FODMAP	 restriction	 improves	 symptoms,	 (ii)	 long-	term	
effects/safety in terms of gut microbiota and potential nutritional 
deficiencies, (iii) standardization of a reintroduction protocol, (iv) 
whether	 or	 not	 complete	 exclusion	 of	 all	 FODMAPs	 is	 necessary	
for full clinical benefit, and (v) improving patient selection to enrich 
symptom response. These questions are linked, and as we deter-
mine	the	mechanism(s)	by	which	FODMAP	exclusion	alleviates	IBS	
symptoms, the answers to the remaining questions will become more 
apparent.
If an IBS patient improves with the full elimination of dietary 
FODMAPs,	a	reintroduction	phase	begins	to	determine	an	individual	
patient’s	FODMAP	intolerances.	Given	both	the	concerns	about	long-	
term	effects	of	 the	 low	FODMAP	diet	on	 the	microbiota	 and	over-
all nutrition, as well as the restrictive nature of the diet, the full low 
FODMAP	diet	 is	not	meant	to	serve	as	a	 long-	term	solution	for	pa-
tients	with	IBS.	The	current	means	by	which	FODMAP	reintroduction	
is conducted varies dramatically from center to center and is driven by 
the biases and clinical experiences of providers rather than evidence. It 
is a poorly defined trial- and- error process which is clearly suboptimal 
and may expose patients to prolonged or even unnecessary suffer-
ing	as	they	try	to	identify	their	personal	FODMAP	triggers.	There	are	
currently little scientifically rigorous data to allow an evidence- based 
approach	 to	FODMAP	 reintroduction	and	consequently,	 there	 is	no	
widely accepted protocol for this process. This leaves providers to de-
velop their own non- evidence based protocols to address the com-
plexities surrounding (i) specific foods used to challenge patients, (ii) 
FODMAP	dose,	and	(iii)	duration	of	exposure.	Generating	a	structured	
reintroduction protocol for clinical practice would serve as a construct 
for clinicians worldwide to guide dietitians and patients during this 
process. In addition, further investigative efforts should be made to 
determine if the observed changes in the microbiota mitigated by the 
low	FODMAP	diet	remain	once	certain	FODMAPs	are	re-	introduced	
to tolerance.
One could image a future where it may then be possible to con-
struct	a	less	restrictive	version	of	the	low	FODMAP	diet,	which	offers	
similar clinical benefits to most IBS patients. Determining a less re-
strictive	version	of	the	low	FODMAP	diet	could	improve	adherence,	
create wider appeal, and ease the financial and logistic burden for this 
dietary approach. Facebook, Netflix, and Google currently curate user 
content based on our demographics, past purchases, and search his-
tories. There is no reason then that we as clinicians cannot grasp the 
tools to do the same for our patients: to curate their care based on 
their preferences, symptoms, and biomarker data including stool and 
metabolomic profiles.
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